Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

By L. Abrey, T. Batchelor, A. Ferreri, M. Gospodarowicz, E. Pulczynski, E. Zucca, Justin R. Smith, A. Korfel, C. Soussain, L. Deangelis and 10 more. Journal of Clinical Oncology, 2005

808 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/d51991a6ac1a55e9a9182a4974b502d793e486f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Stroobants
2. M. Juweid
3. L. Specht
4. B. Cheson
5. B. Coiffier
6. B. Pfistner
7. M. Federico
8. J. Connors

Citations in the corpus

• High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. (2009, neutral): “28 Second, we did not use the criteria from the International Primary CNS Lymphoma Collaborative Group (IPCG) for response assessment and definition 29 since they were published after this trial was started.”
• Revised response criteria for malignant lymphoma. (2007, background): “Primary CNS Lymphomas Recommendations of the International Workshop on Evaluation of Primary Central Nervous System Lymphomas were adopted in their entirety.(37)”
• Primary central nervous system lymphoma. (2008, background): “Primary CNS lymphoma may present either as an isolated lesion or as a combination of the following features: (1) discrete or diffuse intracranial lesions that are either solitary or multiple, (2) ocular lymphomas with or without other lesions, and (3) leptomeningeal surface and spinal cord lesions.”